Sign In to Request a Protocol
Sign In to Request a Protocol

AOD-9604 (2 mg Vial) Protocol

  • Table of Contents

AOD-9604 (2 mg Vial)

AOD-9604 is Research Information at 300 mcg–500 mcg daily via subcutaneous Research Procedure in educational protocols. A 2 mg vial Research Preparation Information with bacteriostatic water yields about 0.667 mg/mL. This information is for research and educational use only.

  • Research Preparation Information:: Add 3.0 mL bacteriostatic water → ~0.667 mg/mL (667 mcg/mL) concentration.
  • Typical daily range: 300–500 mcg once daily (gradual titration).
  • Easy measuring: At 0.667 mg/mL, 1 unit = 0.01 mL ≈ 6.67 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

AOD-9604 Research Information protocols leverage this synthetic 16‑amino‑acid fragment (Tyr‑hGH 177–191) to support lipolysis (fat breakdown) and inhibit lipogenesis (fat storage) without elevating IGF‑1 levels or causing insulin resistance. Clinical trials have demonstrated that AOD‑9604 exhibits a placebo‑like safety profile in obese adults, making it a well‑tolerated option for metabolic support. This educational protocol outlines a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

  • Research Information Guide

Educational guide for reconstitution and daily Research Information

Standard / Gradual Approach (3 mL = ~0.667 mg/mL)

PhaseDaily BlendVolume (mL)
Weeks 1–2300 mcg45 units (0.45 mL)
Weeks 3–4500 mcg75 units (0.75 mL)

Frequency: Inject once daily subcutaneously (typically in the morning on an empty stomach). This schedule uses the largest practical dilution (3.0 mL) to keep Research Procedure units ≥10 for better accuracy. Rotate Research Procedure sites (abdomen, thighs, upper arms) to minimize local irritation.

Reconstitution Steps

  • 1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  • 2. Inject slowly down the vial wall; avoid foaming.
  • 3. Gently swirl/roll until dissolved (do not shake).
  • 4. Label and refrigerate at 2–8 °C (35.6–46.4 °F) , protected from light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

  • Research Requirements
Plan based on an 8–12 week daily protocol with gradual titration (300 mcg Weeks 1–4, 500 mcg Weeks 5+).
  • Peptide Vials (AOD-9604, 2 mg each):
  • 8 weeks ≈ 12 vials
  • 12 weeks ≈ 19 vials
  • 16 weeks ≈ 26 vials
  • Insulin Syringes (U-100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
  • 8 weeks (12 vials): 36 mL → 4 × 10 mL bottles
  • 12 weeks (19 vials): 57 mL → 6 × 10 mL bottles
  • 16 weeks (26 vials): 78 mL → 8 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the Research Procedure site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
  • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
  • 16 weeks: 224 swabs → recommend 3 × 100-count boxes
  • Protocol Overview
Concise summary of the once‑daily regimen.
  • Goal: Goal: Support reduction of fat mass and enhance fat oxidation over time.
  • Schedule: Daily subcutaneous Research Procedure for 8–12 weeks (extend to 16 weeks if desired)..
  • Research Information: 300–500 mcg daily with gradual titration.
  • Research Preparation Information: 3.0 mL per 2 mg vial (~0.667 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen; Research Preparation Information: refrigerated; avoid repeated freeze–thaw.
  • Research Overview
Suggested daily titration approach.
  • Start: 300 mcg daily for Weeks 1–4; increase to 500 mcg for Weeks 5–12 as tolerated.
  • Target: 500 mcg daily by Week 5 and maintain through cycle completion.
  • Frequency: Once per day (subcutaneous).
  • Cycle Length: 8–12 weeks; optional extension to 16 weeks.
  • Timing: Morning administration (fasted) is common; rotate Research Procedure sites.
  • Storage Instructions
Proper storage preserves peptide quality.
  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable for 1+ year.
  • Research Preparation Information: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks and avoid freeze–thaw.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.
  • Important Notes
Practical considerations for consistency and safety.
  • Use new sterile insulin syringes (U‑100, 29–31 gauge); dispose in a sharps container.
  • Rotate Research Procedure sites (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy.
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Each 2 mg vial provides approximately 4 days of Research Information at 500 mcg/day or 6–7 days at 300 mcg/day.
  • How This Works

AOD‑9604 is a modified C‑terminal fragment of human growth hormone that retains the lipolytic (fat‑reducing) domain without the growth‑promoting effects. It binds to adipose tissue and triggers breakdown of stored fat while blocking new fat storage (re‑esterification) in adipocytes. At the molecular level, chronic AOD‑9604 administration upregulates β3‑adrenergic receptors in fat tissue, reversing obesity‑related suppression of these fat‑burning receptors. Unlike full‑length hGH, AOD‑9604 does not meaningfully elevate IGF‑1 levels or worsen glucose tolerance, making its tolerability indistinguishable from placebo in human trials.

  • Potential Benefits & Side Effects
Observations from preclinical and early research literature.
  • Supports reductions in fat mass and increases in fat oxidation over time; clinical trials showed modest but statistically significant weight loss (approximately 2.6 kg vs. 0.8 kg placebo over 12 weeks at 1 mg/day).
  • Preferential loss of abdominal fat observed, resembling the pattern seen with low‑Research Information hGH therapy.
  • Does not meaningfully raise IGF‑1 and shows a placebo‑like safety profile in human studies; no anti‑AOD9604 antibodies detected.
  • Emerging regenerative potential: preclinical studies suggest possible cartilage repair and bone health benefits.
  • Generally well tolerated; occasional mild Research Procedure‑site reactions (redness/itch) may occur with subcutaneous administration.
  • Lifestyle Factors
Complementary strategies for best outcomes.
  • Pair with a hypocaloric, protein‑forward diet tailored to energy needs; AOD‑9604 is best viewed as a supportive aid to fat loss rather than a stand‑alone solution.
  • Combine resistance training and aerobic activity to reinforce metabolic adaptations.
  • Prioritize sleep and stress management to support adherence and recovery.
  • Scientific Research Information
General subcutaneous guidance from clinical best‑practice resources.
  • Clean the vial stopper and skin with alcohol; allow to dry completely.
  • Pinch a skinfold; insert the needle at 90° (or 45° if very little subcutaneous fat) into subcutaneous tissue.
  • Do not aspirate for subcutaneous Research Procedure; inject slowly and steadily
  • Rotate sites systematically (abdomen at least 2 inches from navel, thighs, upper arms) to avoid lipohypertrophy.
  • Recommended Source
We recommend Vitality Labs Peptides for high-purity 5-Amino-1MQ (50 mg).
  • High-purity, third-party-tested lots with batch COAs.
  • Consistent, ISO-aligned handling and documentation.
  • Reliable fulfillment to maintain cold-chain integrity.
Contact on Telegram
  • Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
  • References

Explore related research Research Information protocols and background reading for BPC-157 + TB-500.

Journal of Endocrinology and Metabolism (2014)

— Safety and metabolism of AOD9604 as a nutraceutical ingredient; mechanism of action and metabolic studies
More Info

Journal of Endocrinology and Metabolism (2013)

— Safety and tolerability of AOD9604 in humans; no IGF‑1 increase; placebo‑like safety profile
More Info

FDA Pharmacy Compounding Advisory Committee (2024)

— AOD‑9604 bulk drug substance meeting memorandum; regulatory and safety overview
More Info

Endocrinology (OUP)

— Effects of hGH and AOD9604 on lipid metabolism in obese mice; β‑adrenergic pathway mechanisms
More Info

Bachem Peptide Guide

— Effects of hGH and AOD9604 on lipid metabolism in obese mice; β‑adrenergic pathway mechanisms
More Info

Creative Peptides

— Peptide stability and shelf life; Research Preparation Information solution storage guidelines
View Reference

More Info

Olympia Pharmacy

— How to administer a subcutaneous Research Procedure; site rotation and hygiene
View Reference

More Info

Endocrinology (OUP)

— Chronic AOD9604 treatment in obese and β3‑AR knockout mice; receptor upregulation
More Info

Gastroenterology

— Drug treatment of the overweight patient; AOD‑9604 RCT summary and clinical efficacy
More Info

Annals of Clinical and Laboratory Science (PubMed)

— Effect of intra‑articular AOD9604 with hyaluronic acid in rabbit osteoarthritis model
More Info

DrugBank

— AOD9604 drug summary; mechanism of action, bone and metabolic effects
More Info

CDC

– Vaccine administration: subcutaneous route; no aspiration required
View Reference

More Info

Vitality Lab Peptides

— 5-Amino-1MQ (50 mg) Research (quality and batch documentation)

More Info